Nama Insights

Virtus LifeSci Biotech Clinical Trials ETF (BBC)

Health · Virtus · NYSE

HealthETF
Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund in the Health category. It has $52.68M in assets, an expense ratio of 0.65% and a 1.24% dividend yield. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Assets under management$52.68M
Expense ratio0.65%
CategoryHealth
Dividend yield1.24%
NAV$49.04
Fund familyVirtus
ExchangeNYSE

Top holdings

The largest positions Virtus LifeSci Biotech Clinical Trials ETF reports, by weight.

HoldingNameWeight
DFTX Definium Therapeutics Inc Ordinary Shares 1.18%
SLS SELLAS Life Sciences Group Inc 1.17%
RGNX Regenxbio Inc 1.12%
QURE uniQure NV 1.04%
MBX MBX Biosciences Inc 0.97%
MNPR Monopar Therapeutics Inc 0.96%
FDMT 4D Molecular Therapeutics Inc Ordinary Shares 0.94%
APGE Apogee Therapeutics Inc 0.93%
ABCL AbCellera Biologics Inc Ordinary Shares 0.93%
AKTS Aktis Oncology Inc 0.91%

Other Health ETFs

Explore live BBC data on Nama Insights →